Here are the 424B prospectus supplements from Quest Diagnostics Inc. (DGX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow DGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DGX filings page.
Quest Diagnostics Incorporated is offering $500,000,000 aggregate principal amount of 5.000% senior notes due June 30, 2036. The notes accrue interest from May 6, 2026, pay semiannually and were priced at 98.751% of principal. Net proceeds are estimated at $490,505,000 and are expected to be used for general corporate purposes, which may include repayment of the $500,000,000 3.45% Senior Notes maturing on June 1, 2026. The notes are senior unsecured, will rank equally with other senior unsecured obligations, and will be issued in book-entry form through DTC. The offering includes customary redemption features, a change-of-control repurchase at 101%, and covenants limiting liens and certain sale-and-leaseback transactions.
Quest Diagnostics Incorporated is offering senior unsecured notes under a preliminary prospectus supplement dated April 27, 2026. The prospectus supplement describes the notes’ general terms including semiannual interest, optional redemption (including a Par Call Date provision), and a Change of Control repurchase right at 101% of principal plus accrued interest. Net proceeds are expected to be used for general corporate purposes and may include repayment of the Company’s $500 million 3.45% Senior Notes due June 1, 2026. The notes will rank equally with Quest Diagnostics’ other senior unsecured obligations and be structurally subordinated to subsidiary indebtedness. The prospectus incorporates by reference the Company’s 2025 Form 10-K risk factors and other filings.